By Fineline Cube Zai Lab (NASDAQ: ZLAB; HKG: 9688) announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to zocilurtatug pelitecan (zoci, formerly known as ZL-1310) for the treatment of neuroendocrine carcinoma (NEC).
Regulatory Milestone
| Item | Detail |
|---|---|
| Company | Zai Lab (NASDAQ: ZLAB; HKG: 9688) |
| Product | Zocilurtatug pelitecan (zoci, formerly ZL-1310) |
| Regulatory Status | FDA Orphan Drug Designation (ODD) |
| Indication | Neuroendocrine carcinoma (NEC) |
| Announcement Date | 3 Aug 2026 |
| Product Type | Delta-like ligand 3 (DLL3)-targeting antibody-drug conjugate (ADC) with first-in-class potential |
Previous Regulatory Designations
- US FDA: Previously granted Fast Track Designation (FTD) for extrapulmonary neuroendocrine carcinomas (epNECs)
- US FDA: Previously granted FTD and ODD for small cell lung cancer (SCLC)
- EMA: Granted Orphan Drug Designation for pulmonary neuroendocrine carcinoma
Strategic Significance
The FDA’s Orphan Drug Designation is granted to drugs and biologics intended for the treatment, diagnosis, or prevention of rare diseases or disorders affecting fewer than 200,000 people in the United States. This designation provides Zai Lab with certain benefits, including:
- Seven years of market exclusivity upon regulatory approval
- Tax credits for qualified clinical trials
- Potential waiver of certain application fees
Neuroendocrine carcinomas represent a rare and aggressive subset of neuroendocrine tumors characterized by high-grade malignancy and poor prognosis. Current treatment options for patients with advanced NEC remain limited, highlighting the urgent need for novel therapeutic approaches.
Market Opportunity & Competitive Landscape
- Rare Disease Market: Orphan drug designations provide significant commercial advantages through market exclusivity
- Unmet Medical Need: Limited treatment options for advanced NEC create substantial opportunity for effective therapies
- Competitive Positioning: First-in-class DLL3-targeting ADC with multiple regulatory designations across different indications
- Commercial Potential: Orphan drug status enhances reimbursement prospects and premium pricing opportunities
Company Pipeline Strategy
“Receiving Orphan Drug Designation for zocilurtatug pelitecan underscores the significant unmet medical need in neuroendocrine carcinoma and validates our commitment to developing targeted therapies for rare cancers,” said Dr. Samantha Du, Founder, Chairperson, and CEO of Zai Lab. “This important regulatory milestone supports our ongoing clinical development program and brings us one step closer to potentially offering a new treatment option for patients battling this devastating disease.”
Zocilurtatug pelitecan is an investigational antibody-drug conjugate (ADC) designed to selectively target tumor cells expressing specific surface markers associated with neuroendocrine carcinomas. The compound leverages Zai Lab’s proprietary technology platform to deliver a potent cytotoxic payload directly to cancer cells while minimizing exposure to healthy tissues.
Forward‑Looking Statements
This brief contains forward-looking statements regarding regulatory designations, clinical development, and commercial expectations. Actual results may differ due to clinical trial outcomes, regulatory decisions, competitive dynamics, and market adoption.-Fineline Info & Tech